Objective-Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a circulating protein that influences plasma low-density lipoprotein concentration and susceptibility to coronary heart disease. Circulating PCSK9 levels show considerable interindividual differences, but the factors responsible for this variation are largely unknown. Methods and Results-We analyzed circulating PCSK9 levels in 4 cohorts of healthy, middle-aged Swedes (n=5722) and found that PCSK9 levels varied over ≈50-fold range, showed a positive relationship with plasma low-density lipoproteincholesterol concentration, and were associated with plasma triglyceride, fibrinogen, insulin, and glucose concentrations.
P
CSK9 is a circulating protein, synthesized predominantly in the liver, 1 involved in the regulation of the plasma low-density lipoprotein (LDL)-cholesterol concentration and associated with susceptibility to coronary heart disease (CHD). 2, 3 Proprotein convertase subtilisin/kexin type 9 (PCSK9) shortens the half-life of the LDL-receptor (LDLR), 4 a process independent of its catalytic activity. 5 Human studies demonstrated that dominant gain-of-function mutations of PCSK9 cause familial hypercholesterolemia and CHD, 6 whereas loss-of-function mutations are associated with hypocholesterolemia and protection from CHD. 7 Studies in experimental animals corroborated these observations. Overexpression of PCSK9 in mice greatly reduced hepatic LDLR expression and was associated with increased plasma LDL concentration, 8, 9 whereas PCSK9 deficiency resulted in a significantly increased hepatic LDLR number. 10 Parabiosis experiments in mice confirmed that circulating PCSK9 is involved in the degradation of hepatic LDLR. 11 Overall, these results are compatible with the notion that circulating PCSK9 regulates plasma LDL concentration through regulation of the LDLR density on the plasma membrane. PCSK9 is therefore considered a promising target to treat hypercholesterolemia and prevent CHD. 12 Circulating PCSK9 levels have been measured in healthy, middle-aged individuals of European descent, [13] [14] [15] [16] [17] in children and adolescents, 18 and in Chinese 19 and ethnically diverse 20 cohorts. The general findings of these studies are that the circulating PCSK9 levels vary over a wide range among apparently healthy subjects and correlate with the plasma LDL concentration. The nature of the remarkable interindividual variation in circulating PCSK9 level is not known, but it is generally assumed that genetic factors contribute to this variability. However, only 1 high-impact genetic variant associated with circulating PCSK9 levels 16, 20 has thus far been identified in whites, the low-frequency PCSK9-R46L variant. 7 The minor allele of this polymorphism has a frequency of 1% to 2% in European populations, 21 indicating that it explains only a minor fraction of the variation in circulating PCSK9 level in healthy subjects. This suggests that other, as yet unknown, genetic variants contribute to the interindividual variation in circulating PCSK9 level. Here, we analyzed the role of genetic variation for circulating PCSK9 levels using a genome-wide association study (GWAS) approach (n=1215) and by using dense mapping of the PCSK9 locus in 4 cohorts of apparently healthy, middle-aged, predominantly Swedish subjects (n=5722).
Methods subjects and Biochemical Assays
Biobanks and databases originating from 4 population-based studies of middle-aged subjects from the greater Stockholm area were used. The first cohort (POLCA) consists of 649 healthy 50-year-old men, free from CHD, who had been recruited at random using the population registry. 22 The second cohort (acronym: OLIVIA) comprises 340 men and 340 women with a similar age distribution (33-80 years), recruited according to the same principles for inclusion in the PROCARDIS program. 23 A third cohort (acronym: CORONA) consists of 750 healthy men, free from CHD, aged between 40 and 65 years (with 30 subjects for every age group), who had been recruited at random using the population registry. The fourth cohort (acronym 60YO) was derived from a population-based, cross-sectional study of a total of 4232 60-year-old men and women. 24 Subjects on statin medication, with manifest diabetes mellitus, of non-European descent, or with incomplete genotype data were excluded from all analyses. Overall, a total of 624 subjects from POLCA, 591 subjects from OLIVIA, 719 subjects from CORONA, and 3788 subjects from 60YO were evaluated.
Standardized protocols, approved by the Ethics Committee of the Karolinska Institute, regulated recruitment procedures; acquisition of socioeconomic, lifestyle, and medical data through comprehensive questionnaires; blood sampling; clinical investigations; and the management of databases and biobanks. All subjects gave their informed consent to participation. Venous blood samples were obtained after an overnight fast. Plasma and serum intended for the biobank were aliquoted and stored at −70°C until analysis. Standard lipid analysis was performed with automated commercial assays, and apolipoprotein B was determined by an immunoturbidometric assay. 22 Plasma insulin concentration was measured by ELISA based on a monoclonal antibody (DAKO Ltd for POLCA and DakoCytomation Ltd for OLIVIA, Dako, Ely, Cambridgeshire, UK). Plasma concentrations of high-sensitivity C-reactive protein and fibrinogen were determined by immunoturbidometric assays. Serum PCSK9 concentration was determined as described by Alborn et al. 13 
expression Analysis of Human liver Biopsies
Liver biopsies were obtained from patients undergoing aortic valve surgery at the Karolinska University Hospital, Stockholm, Sweden, as part of the Advanced Study of Aortic Pathology. 25 The protocol was approved by the ethics committee of the Karolinska Institutet, and informed consent was obtained from all participants according to the Helsinki Declaration. RNA samples were hybridized and scanned at the Karolinska Institutet microarray core facility using Affymetrix GeneChip Human Exon 1.0 ST (Affymetrix, Santa Clara, CA) arrays and protocols. The cell-files were preprocessed using Robust Multichip Average normalization as implemented in the Affymetrix Power Tools 1.10.2 package apt-probeset-summarize. mRNA values are reported in arbitrary units of logarithmic transformed data.
Genotyping
Genome-wide genotyping was performed at the single nucleotide polymorphism (SNP) Technology Platform, Uppsala University, Sweden, using the Illumina (San Diego, CA) Infinium II Human 1M Beadchip for the OLIVIA cohort whereas the Illumina Infinium 610K quad Beadchip was used for the POLCA cohort. Genotype assignment for both cohorts was performed using the Beadstudio calling algorithms. SNPs with a call rate <90%, minor allele frequency <5%, or with a Hardy-Weinberg equilibrium P value of <1.0×10 −6 were filtered out before the analysis, giving ≈530k SNPs for analysis in the combined POLCA-OLIVIA data set. Samples with genotype calls <95% were excluded from further analysis, as were male samples with significant X-chromosomal heterozygosity and samples with confirmed nonwhite descent or cryptic relatedness. Imputation was carried out on the quality-controlled genotypes of the combined POLCA-OLIVIA data set. Approximately 2.4 million autosomal SNPs were imputed with the HapMap II CEU phased reference panel, using MACH. SNPs with r 2 hat<0.3 (reflecting low confidence in imputation quality) or ambiguous strand or mapping annotation were excluded.
The 
results relationships of clinical and Biochemical Parameters to serum PcsK9 concentration
The characteristics of the 4 study populations are summarized in Table 1 . All subjects in the 4 cohorts were Europeans, and the vast majority of subjects were of Swedish descent. The distributions of circulating PCSK9 levels in all 4 cohorts varied over a 50-fold range and were skewed to the right. The influence of age was analyzed in the OLIVIA and CORONA cohorts, whereas all subjects in the POLCA and 60YO cohorts were aged 50 and 60 years, respectively. No significant relationship was observed between age and circulating PCSK9 level (data not shown).
Subset analyses with respect to sex, smoking, and ethnicity were restricted to the largest cohort (60YO). Spearman rank correlation coefficients between clinical and biochemical parameters and circulating PCSK9 levels are given in Table 2 . Significant correlations with circulating PCSK9 levels were consistently observed in all cohorts for the plasma triglyceride, cholesterol, LDL cholesterol, and apolipoprotein B concentrations. Significant correlations were also found in some of the cohorts for body mass index and fasting glucose, insulin, C-reactive protein, and fibrinogen concentrations.
Western Blot Analysis of PcsK9 in subjects With extreme levels of circulating PcsK9
The wide range of circulating PCSK9 levels raises the question of whether major structural variation in the PCSK9 protein could account for this phenomenon. We, therefore, performed immunoprecipitation and Western blotting analysis of PCSK9 in blood samples from subjects with extreme levels of circulating PCSK9, as illustrated in Figure I in the online-only Data Supplement. As reported previously, 12 3 bands were visualized in all samples, representing mature PCSK9, a band described as a furin cleavage product of PCSK9, 17 and PCSK9 propeptide. However, no apparent differences in the sizes of these bands were noted, and overall comparable ratios were observed of the intensities of the mature PCSK9 to the furin cleavage product of PCSK9.
GWAs for circulating PcsK9 levels
A GWAS was performed on genotyped data in the combined POLCA and OLIVIA cohorts in order to identify novel genetic loci associated with circulating PCSK9 levels. As shown in Figure 1 , no genetic marker reached the conventional level for genome-wide significance of P<5.0×10 −8 . The analysis was repeated using imputed SNP data, but no additional SNPs were found to be associated with circulating PCSK9 level with significance of P<1.0×10 −4 . Nineteen genotyped SNPs with P<1.0×10 −4 in the GWAS were also analyzed in the CORONA cohort. As shown in Table I in the online-only Data Supplement, none of these SNPs showed a significant relationship with circulating PCSK9 levels in CORONA. As a complementary approach, we evaluated the consistency of the relationships between SNPs and circulating PCSK9 level when additional covariates (plasma triglyceride, insulin, and (Table II in the online-only Data Supplement). All 4 SNPs were genotyped in CORONA in the previous analysis. Additional genotyping of these SNPs in the 60YO cohort found no evidence for relationships with circulating PCSK9 levels (data not shown).
Association Between PcsK9-r46l and circulating PcsK9 levels
PCSK9-R46L (rs11591147) was then analyzed in all cohorts, because it was reported that whites heterozygous for the PCSK9 variant are characterized by a reduced median plasma level of PCSK9. 16, 20 Carriers of PCSK9-R46L showed significantly reduced circulating PCSK9 levels (P value 0.0419, 0.0127, 0.0117, and <0.0001) in the POLCA, OLIVIA, CORONA, and 60YO cohorts, respectively. Of note, inclusion of the low-frequency rs11591147 SNP in the GWAS would Figure 1 . P values for association with circulating proprotein convertase subtilisin/kexin type 9 (PCSK9) levels in the genome-wide association study (GWAS). Association results by chromosome. The -log 10 of the P value is shown for genotyped single nucleotide polymorphisms (SNPs). The blue horizontal line corresponds to -log10=4.0, the threshold used for identifying SNPs for replication. have led to identification of the PCSK9 locus using the GWAS evaluation protocol used in this report.
dense Mapping of the PcsK9 locus
We generated a dense SNP map of the PCSK9 locus to evaluate the possible contribution of other SNPs, in addition to PCSK9-R46L (rs11591147), to circulating PCSK9 levels. Initial analysis of genotyped data in the POLCA-OLIVIA cohort identified 8 SNPs associated with a P<0.05 level with circulating PCSK9 levels ( ), and rs2479409 (P=3.00×10 −4 ), as shown in Table 3 . The 3 SNPs were forwarded to a further replication stage in the 60YO cohort. In the combined analysis of discovery and replication cohorts (Table 4) , rs11591147 and rs2479415 were significantly associated with circulating PCSK9 levels, whereas rs2479409 failed to reach the Bonferroni-corrected significance level (P<1.85×10 −3 ). As shown in Table 4 , it is notable that the direction of effect and effect size differ between rs11591147 and rs2479415. Whereas the minor allele of the low-frequency rs11591147 SNP is strongly associated with decreased circulating PCSK9 levels, the minor allele of the common rs2479415 SNP is moderately associated with increased circulating PCSK9 levels. The rs11591147 and rs2479415 SNPs have  values of −0.100 and 0.054, respectively, and account for 0.9% and 0.2%, respectively, of the variation in circulating PCSK9 levels. The genetic architecture of the PCSK9 gene is illustrated for the genotyped SNPs in Figure 2 and for the genotyped plus imputed SNPs in Figure II in the online-only Data Supplement. The rs11591147 and rs2479415 SNPs have an R 2 value of 0.01, underlining the independent nature of the 2 variants. However, conditional analysis (adjusting for either rs11591147 or rs2470415) indicates that the 2 SNPs are not entirely independent from each other; the P value for the association with circulating PCSK9 levels was reduced from 
sNP Associations With Metabolic Traits
The rs11591147 and rs2479415 SNPs were further analyzed for association with metabolic traits (Table 4) . Rs2479415 demonstrated a weak association with LDL cholesterol, whereas rs11591147, in line with previous publications, 7, 21 was strongly associated with the plasma LDL-cholesterol concentration. Rs2479415 showed a modest association with circulating insulin levels, whereas no relationship was found between rs11591147 and plasma insulin concentration. No relationships were found between the rs11591147 and rs2479415 polymorphisms and the plasma triglyceride (Table 4) , glucose and fibrinogen (data not shown) concentrations.
Association Between rs2479415 sNP and Hepatic PcsK9 mrNA levels
The relationships between hepatic PCSK9 mRNA levels and the rs11591147 and rs2479415 SNPs were analyzed in liver samples obtained from 199 patients undergoing aortic valve surgery. As expected, hepatic PCSK9 mRNA levels (mean±SD) were significantly higher (P<0.0001) in statin users (7.26±0.24 arbitrary units, n=68) as compared with subjects without statin medication (7.05±0.22 arbitrary units, n=131). No relationship was found between rs11591147 SNP and hepatic PCSK9 mRNA levels. However, in both the statin-treated and nontreated subgroups, a graded association was observed between rs2479415 SNP and hepatic PCSK9 mRNA levels, ie, subjects homozygous for the minor allele had a greater increase in PCSK9 mRNA levels as compared with subjects heterozygous for the rs2479415 SNP. The statin-adjusted hepatic PCSK9 mRNA levels (n=199) for the rs2479415 C/C, T/C, and T/T genotypes were 7.00±0.21, 7.05±0.23, and 7.12±0.20 arbitrary units (mean±SD), respectively (P<0.01).
discussion
The aim of this study was to uncover genetic factors that contribute to the marked interindividual variation in circulating PCSK9 in the general population. To this end, we analyzed circulating PCSK9 levels in 4 cohorts of healthy, middle-aged Swedish subjects. In total, 5722 subjects were evaluated in this study, rendering it the largest analysis of circulating PCSK9 levels conducted thus far. In agreement with smaller studies in white subjects, [13] [14] [15] [16] [17] circulating PCSK9 levels were found to vary over a wide range. Moreover, this study confirmed previous reports demonstrating a positive relationship between the circulating PCSK9 level and the plasma LDL concentration and provided further evidence for associations between circulating PCSK9 levels and the plasma triglyceride, fibrinogen, insulin, and glucose concentrations. [13] [14] [15] [16] [17] [18] [19] [20] In this study we used, for the first time, the GWAS approach to identify common genetic loci contributing to the regulation of the circulating PCSK9 level. No genome-wide significant loci were encountered. However, with a discovery cohort consisting of 1215 subjects, we had limited power to detect common SNPs with a modest impact on circulating PCSK9 levels. Nevertheless, Carrasquillo et al 26 were able to identify a genetic locus for plasma progranulin levels in a GWAS involving only 533 control subjects, and we confirmed the association between the apolipoprotein E-C1 locus and the plasma apolipoprotein E concentration, using the same discovery cohort used in the present study (F.M.v.H., unpublished observation). Moreover, inclusion of the SNP for PCSK9-R46L (rs11591147) in the GWAS analysis performed in this report would have led to the identification of the PCSK9 locus. Thus, our failure to identify 60YO indicates Stockholm study of 60-year-old men and women; LDL-C, low-density lipoprotein cholesterol; P-O-C, POLCA-OLIVIA-CORONA; PCSK9, proprotein convertase subtilisin/kexin type 9; SNP, single nucleotide polymorphism.
PCSK9 levels were adjusted for study, age, sex, Swedish origin, and smoking.
by guest on January 22, 2018 http://atvb.ahajournals.org/ Downloaded from genetic loci besides PCSK9 suggests that common genetic variants have a modest impact on the circulating PCSK9 levels. Identification of such genetic loci will therefore require considerably larger discovery cohorts.
Several recent GWAS have demonstrated an association between the PCSK9 locus and the plasma LDL-cholesterol concentration. [27] [28] [29] It is possible that the PCSK9-R46L variant is responsible for this relationship, but it is noteworthy that (1) the minor allele frequency of PCSK9-R46L is relatively low (1.9% in the present study) and (2) the minor allele is associated with reduced plasma LDL-cholesterol levels and not with increased plasma LDL-cholesterol concentrations as observed for the PCSK9 SNPs in GWAS. [27] [28] [29] We, therefore considered the possibility that the PCSK9 locus harbors another functional SNP influencing the circulating PCSK9 level. Accordingly, a dense SNP map of the PCSK9 locus was generated with special focus on SNPs with reported associations with the plasma LDL-cholesterol concentrations, [27] [28] [29] [30] [31] [32] and the relationships with circulating PCSK9 levels were evaluated. No evidence was found for a relationship between circulating PCSK9 levels and rs11206510, a SNP located ≈9 kb upstream of PCSK9, previously shown to be associated with plasma LDL-cholesterol concentration. 27, 28, 31 Likewise, no significant relationship was found between circulating PCSK9 levels and rs2479409, a SNP in the proximal promoter of PCSK9 recently identified in a large GWAS meta-analysis for blood lipids. 29 The major finding of this study is the identification of the rs2479415 polymorphism in the PCSK9 locus as an independent determinant of circulating PCSK9 levels. The rs2479415 polymorphism is, in contrast to the PCSK9-R46L variant, a common SNP. Moreover, the minor allele of rs2479415 is associated with increased circulating PCSK9 levels and increased plasma LDL-cholesterol concentrations, 32 whereas the PCSK9-46L allele is related to decreased circulating PCSK9 levels and reduced plasma LDL-cholesterol concentrations. This suggests that the rs2479415 polymorphism, together with the PCSK9-R46L variant, contributes to the observed association between the PCSK9 locus and the plasma LDL-cholesterol concentration.
The rs2479415 polymorphism is located ≈6 kb upstream of the PCSK9 transcriptional start site, indicating that this polymorphism could play a role in the regulation of PCSK9 transcription. Expression studies in human liver samples, indeed, demonstrated that the minor allele of rs2479415 is associated with increased hepatic PCSK9 mRNA levels, in line with the observed relationships between rs2479415 and circulating PCSK9 levels and LDL-cholesterol concentrations. Imputation analysis did not uncover alternative SNPs responsible for the observed relationship between rs2479415 and circulating PCSK9 levels. Overall, these observations suggest that rs2479415 is the putative functional genetic variant, influencing the rate of transcription of PCSK9 in the liver, which in turn affects circulating PCSK9 levels, ultimately leading to variation in the plasma LDL-cholesterol concentration.
This report provides further evidence for a relationship between circulating PCSK9 and plasma triglyceride levels. The physiological basis for this relationship has not been resolved. Nevertheless, several recent studies demonstrated that PCSK9, in addition to its role in the LDL-receptor pathway, influences the rate of synthesis 33 or degradation 34-37 of triglyceride-rich lipoproteins. Here, we show that the minor alleles of the PCSK9-R46L variant and the rs2479415 polymorphism are not associated with the plasma triglyceride concentration. These observations argue against the direct role of PCSK9 in plasma triglyceride metabolism and suggest instead that the plasma triglyceride concentration influences circulating PCSK9 levels.
In summary, this study provides further evidence for considerable interindividual variation in circulating PCSK9 levels in healthy, middle-aged white (predominantly Swedish) subjects. GWAS analysis demonstrated that there are no common variants with a major influence on PCSK9 levels. However, dense mapping of the PCSK9 locus identified a novel, common polymorphism (rs2479415) as an independent determinant of circulating PCSK9 levels. It is proposed that both the rs2479415 polymorphism and the PCSK9-R46L variant contribute to the reported relationships between the PCSK9 locus and the plasma LDL-cholesterol concentration. 
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Immunoprecipitation and Western blotting
Immunoprecipitation (IP) was initiated by adding 100 µL of human serum to 900 µL of immunoprecipitation buffer (50 mM HEPES, 150 mM NaCl, 5 mM EDTA, 5 mM EGTA, and 10 mL of Triton X-100, pH 7. Analysis was performed in the combined POLCA-OLIVIA cohort. PCSK9 levels were adjusted for study, age, gender, Swedish origin, smoking (basic model) and triglycerides, insulin, fibrinogen, SBP or BMI. A1, minor allele; BMI, body mass index; CHR, chromosome; PCSK9, Proprotein convertase subtilisin/kexin type 9; P-O-C, POLCA-OLIVIA-CORONA; SBP, systolic blood pressure; SNP, single nucleotide polymorphism.
